Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 5/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1445778 | 0.89 | CNR2 (0.43) | CNR2NUDT1ALDH1A1LMNATRPA1 | |
| SCHEMBL7913045 | 0.76 | NPC1 (0.44) | CNR2ALDH1A1LMNACYP3A4HSD17B10 | |
| Resorcinol SCHEMBL28316987 | 0.73 | HSD17B1 (0.44) | CA12ALDH1A1CA2LMNACYP3A4 | |
| SCHEMBL31465306 | 0.73 | HSD17B1 (0.53) | CYP3A4CYP1A2CYP2C19HSD17B1HSD17B2 | |
| SCHEMBL6677481 | 0.71 | TYR (0.43) | ALDH1A1GAA | |
| SCHEMBL1534219 | 0.69 | HPGD (0.39) | ALDH1A1CA2LMNACYP3A4HSD17B10 | |
| SCHEMBL27208074 | 0.69 | CNR2 (0.40) | CNR2NUDT1TRPA1ATMP2RX7 | |
| SCHEMBL16731967 | 0.69 | ALDH1A1 (0.32) | ALDH1A1LMNAHSD17B10CYP1A2 | |
| SCHEMBL12483491 | 0.69 | ACHE (0.46) | ALDH1A1LMNAHSD17B10ACHEMAPK1 | |
| SCHEMBL45025 | 0.69 | IDO1 (0.43) | ALDH1A1LMNAHSD17B10MAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2835368-B1 | Process for Isolation of Monophenolic-Bisaryl Triazines | CYTEC TECH CORP (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2835368-A1 | Process for Isolation of Monophenolic-Bisaryl Triazines | CYTEC TECHNOLOGY CORP. (US) | 2015-02-11 | — | — | EP | disclosed |
| EP-1397352-B1 | PROCESS FOR ISOLATION OF MONOPHENOLIC-BISARYL TRIAZINES | CYTEC TECH CORP (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2289884-A1 | Process for isolation of monophenolic bisaryl triazines | CYTEC TECHNOLOGY CORP. (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-2280005-A1 | Process for isolation of monophenolic bisaryl triazines | CYTEC TECHNOLOGY CORP. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20040073028-A1 | Process for isolation of monophenolic-bisaryl triazines | GUPTA RAM BABOO (US) | 2004-04-15 | — | — | US | disclosed |
| EP-1397352-A2 | PROCESS FOR ISOLATION OF MONOPHENOLIC-BISARYL TRIAZINES | Cytec Technology Corp. (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6632944-B2 | Such as 2-(2,4-dihydroxyphenyl)-4,6-bis(2,3-dimethylphenyl)-1,3,5-triazine via solvent extraction; for ultraviolet radiation absorption | CYTEC TECHNOLOGY CORP. | 2003-10-14 | — | — | US | disclosed |
| US-20030013879-A1 | Process for isolation of monophenolic-bisaryl triazines | CYTEC TECHNOLOGY CORP. | 2003-01-16 | — | — | US | disclosed |
| WO-2003000667-A2 | PROCESS FOR ISOLATION OF MONOPHENOLIC-BISARYL TRIAZINES | CYTEC TECHNOLOGY CORP. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073028-A1 | Process for isolation of monophenolic-bisaryl triazines | ADH1C, TET2, AHR | CNR2 1118/4885NUDT1 1395/4885CA12 2583/4885 |
| US-20030013879-A1 | Process for isolation of monophenolic-bisaryl triazines | ADH1C, TET2, AHR | CNR2 1118/4885NUDT1 1395/4885CA12 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.